Incyte's Q2 2026 revenue rose 37.7% to $1.67B, lifted by a $246M one-time Opzelura Medicaid-rebate reversal; excluding it, net sales grew 17% as Jakafi rose 7% and newer drugs jumped 69%, and full-year sales guidance was raised to $5.13–5.26B.
Revenue
$1.7B
+37.7% YoY
Net income
$586M
+44.6% YoY
Diluted EPS
$2.81
+37.7% YoY
Operating margin
41.7%
Overview
Incyte's second quarter of 2026 (three months to June 30) looks bigger on paper than it really was. Total revenue rose 37.7% to $1,674.0 million and GAAP net income rose 44.6% to $585.6 million. However, $246.0 million of that revenue was a one-time accounting reversal tied to a settlement with Medicare/Medicaid regulators over its skin cream Opzelura. Without it, net sales grew 17%, which is still strong. The growth came from three places: Jakafi (up 6.9%), Opzelura's underlying sales (up about 24%), and a group of newer cancer and blood-disorder drugs whose combined sales rose 69%.
The year-ago quarter had a one-off of its own: a $242.3 million gain when Incyte settled a royalty dispute with Novartis. Both quarters therefore carry a windfall of about $245 million. That makes the reported growth in net income and earnings per share a fairer comparison than the revenue line, although for opposite reasons in each year.
Key metrics
Metric
Q2 2026
Q2 2025
YoY Change
Total revenue
$1,674.0M
$1,215.5M
+37.7%
Total net product sales
$1,488.1M
$1,059.4M
+40.5%
Net product sales excl. $246.0M Opzelura reversal
$1,242.1M
$1,059.4M
+17.2%
Jakafi / Jakafi XR net sales
$816.7M
$763.8M
Read 0 community reports on Incyte, or write your own.Write a report
Operating margin is the share of revenue left after the costs of making, researching and selling the drugs, before interest and tax. Both years' margins are inflated by a one-off (see below).
Takeaway: Once the ~$245 million one-offs in each year are removed, Incyte's operating margin rose from about 24% to about 32%. The newer drugs are starting to carry real weight: Opzelura's underlying sales plus the hematology/oncology group came to about $425 million in the quarter, roughly half of Jakafi's $817 million. That matters because the patents protecting Jakafi, still about two-thirds of product sales, expire in 2028.
The one-time items, explained
Q2 2026 — the Opzelura/CMS settlement (+$246.0M revenue). Incyte had sued CMS (the federal agency that runs Medicare and Medicaid) over a rule that treated Opzelura as a "line extension" of Jakafi. The two drugs share the same active ingredient, ruxolitinib: Jakafi is a pill and Opzelura is a cream. Under the rule, Opzelura would owe the larger Medicaid rebates that Jakafi's price history triggers. Incyte had been setting aside money for those possible rebates. In Q2 it reached an agreement under which CMS will not apply the rule to Opzelura. The company reversed the set-aside built up through March 31, 2026, and booked it as $246.0 million of "non-cash" net sales, meaning no cash came in this quarter. Incyte also says it will stop accruing for this and expects a better "gross-to-net" for Opzelura from now on. Gross-to-net is the gap between list price and what the company actually keeps after rebates and discounts. The earnings release puts that ongoing benefit at $15 million in Q2 (already inside the $203.7 million "underlying" figure above) and an estimated $40–50 million over Q3 and Q4 combined.
Q2 2025 — the Novartis royalty settlement (–$242.3M expense). Last year Incyte settled a dispute over how long it owed Novartis royalties on US Jakafi sales. It had accrued $537.1 million, paid $280.0 million, and released the $242.2 million difference as a credit to expenses. The settlement also halved the royalty rate on future US Jakafi sales from January 1, 2025. That royalty was $20.0 million this quarter versus $18.7 million a year ago.
Adjusting both quarters, operating income was about $451.9 million on about $1,428.0 million of revenue in Q2 2026 (≈31.6% margin). In Q2 2025 it was about $288.1 million on $1,215.5 million (≈23.7%). These adjusted figures are our own arithmetic from the filing's line items, not company-reported numbers.
Product by product
Product
Q2 2026
Q2 2025
YoY
Jakafi / Jakafi XR
$816.7M
$763.8M
+6.9%
Opzelura (reported)
$449.7M
$164.5M
+173.4%
Niktimvo
$60.3M
$36.2M
+66.8%
Monjuvi / Minjuvi
$53.7M
$31.1M
+72.5%
Zynyz
$49.9M
$8.9M
+459.9%
Iclusig
$34.4M
$32.7M
+5.1%
Pemazyre
$23.4M
$22.2M
+5.5%
Total net sales
$1,488.1M
$1,059.4M
+40.5%
Jakafi (ruxolitinib pill for the bone-marrow cancers myelofibrosis and polycythemia vera, and for graft-versus-host disease, a complication of bone-marrow transplants) grew because more patients were on it. The 10-Q breaks the $52.9 million increase into +$66.3 million from volume and –$13.4 million from lower net price. It says paid demand rose 9% "across all indications" and that wholesaler inventory was normal, so the growth was not driven by distributors stocking up. Q2 figures include the first sales of Jakafi XR, a once-daily extended-release version the FDA approved in May 2026.
Opzelura (ruxolitinib cream for eczema and vitiligo, a condition that causes patches of skin to lose color): excluding the $246.0 million reversal, sales rose by +$48.2 million from volume and –$9.0 million from price, "primarily due to increased patient demand in the U.S. in both atopic dermatitis and vitiligo." Sales outside the US were $42.9 million, up from $32.3 million, driven by Canada, Italy and new markets.
Newer hematology/oncology drugs (Niktimvo for chronic graft-versus-host disease, Monjuvi for lymphoma, Zynyz for anal and skin cancers): the 10-Q attributes their growth to demand, including recent approvals in follicular lymphoma (Monjuvi, June 2025) and anal-canal cancer (Zynyz, May 2025). It says price changes were "not material." Niktimvo is sold jointly with a partner, and the resulting profit share pushed cost of sales up to $105.0 million from $78.8 million.
Royalties
Incyte also earns royalties on drugs it licensed to other companies. Royalty revenue rose 15.6% to $174.7 million, driven mainly by Jakavi (Novartis's name for Jakafi outside the US), which brought in $124.2 million versus $109.7 million. Royalties from Eli Lilly's Olumiant were $38.5 million versus $33.5 million, and from Novartis's Tabrecta $6.7 million versus $6.6 million. Milestone and contract revenue was $11.2 million versus $5.0 million.
Costs and cash
R&D rose 4.5% to $517.0 million, equal to 30.9% of revenue. Spending on clinical research and outside services was $292.2 million (vs. $286.4 million), which the filing attributes to "continued investment in our late-stage development assets." Salaries rose on higher headcount.
Selling, general and administrative (SG&A) costs rose 6.3% to $351.7 million.
Tax: the effective tax rate fell to about 22.1% from about 27.4%. The 10-Q cites tax credits and foreign tax effects, mostly offset by higher valuation allowances. A valuation allowance is a write-down of tax assets the company may never be able to use.
Cash: $4.5 billion in cash and marketable securities at June 30, up from $3.6 billion at year-end. Operating cash flow was $877.0 million in the first half, versus $310.8 million a year earlier, when the Novartis settlement payment went out. In July Incyte paid $1.25 billion in cash for Vega Therapeutics. No money is borrowed under its $500 million credit line.
The Jakafi patent cliff
Jakafi is the business's foundation. It made up about 66% of Q2 product sales once the Opzelura reversal is excluded. The 10-Q states that Incyte's patents on ruxolitinib's composition of matter (the molecule itself) and on its salt form, including extensions, "currently expire in mid and late 2028, respectively." Its risk factors also note that Jakafi "could face competition from generic products." Opzelura contains the same molecule but is a different product with a different formulation, so the filing's 2028 dates refer to ruxolitinib as Jakafi's active ingredient. Jakafi XR is a new formulation launched in Q2, and the 10-Q does not state separate patent protection for it.
The strategy the filing describes is to replace Jakafi revenue before 2028 with Opzelura, the newer blood-cancer and cancer drugs, and the late-stage pipeline below.
Pipeline milestones stated in the filing
Tafasitamab (Monjuvi) as a first-line lymphoma treatment: the Phase 3 frontMIND trial was positive (January 2026). Regulatory filings were submitted and accepted in Q2 2026, and a US approval and launch are expected in Q1 2027.
Povorcitinib (oral pill for hidradenitis suppurativa, a painful chronic skin disease): the FDA accepted the application in Q1 2026, with possible US approval by Q1 2027. A European application is under review, with possible approval in late 2026.
Opzelura in moderate eczema in Europe: the EMA's scientific committee gave a positive opinion in June 2026, and the European Commission's decision is expected in Q3 2026.
Ruxolitinib cream in hidradenitis suppurativa: topline Phase 3 results (TRuE-HS1/HS2) are expected in Q4 2026.
INCA033989 (targets a CALR mutation that drives some bone-marrow cancers): a Phase 3 trial in essential thrombocythemia started in mid-2026 (the drug has FDA Breakthrough Therapy designation), and a myelofibrosis Phase 3 is planned for the second half of 2026.
Latarcibart (acquired with Vega, for von Willebrand disease, an inherited bleeding disorder): in a Phase 1/2 study it cut the annualized bleeding rate by a median 81%. Phase 3 (VIVID-6) topline data are expected in early 2029.
The earnings release says ten clinical data readouts, four of them from registrational trials, are expected in the second half of 2026.
Guidance and outlook
In the July 28 earnings release (8-K Exhibit 99.1), Incyte raised its full-year 2026 guidance:
Guidance item
Current
Previous
Total net sales
$5,130–5,260M
$4,770–4,940M
Jakafi net sales
$3,220–3,270M (unchanged)
$3,220–3,270M
Opzelura net sales
$1,050–1,100M
$750–790M
Hematology & Oncology net sales
$860–890M
$800–880M
GAAP R&D + SG&A
$4,915–4,995M
$3,495–3,675M
Most of the Opzelura increase comes from the CMS agreement, which the company puts at $300–310 million for the full year. The jump in expense guidance is almost entirely an IPR&D charge of about $1,270 million in Q3 2026 for the Vega purchase. IPR&D, or in-process R&D, is the cost of buying an unapproved drug, which accounting rules require to be expensed immediately instead of spread over time. Guidance also includes $50 million of added latarcibart R&D. Q3 2026 GAAP results will very likely show a large loss because of that charge. It is a one-time accounting cost of the acquisition, not a sign of weakness in the underlying business.
In an August 31, 2026 8-K, Incyte disclosed a separate agreement with CMS. Under it, state Medicaid programs can buy Jakafi and Jakafi XR at prices aligned with those in a group of other wealthy countries. The company said it does not expect this to affect its 2026 guidance or have a material effect on its outlook.
Our read: Jakafi's guidance implies roughly $1,646–1,696 million in the second half, versus $1,574.4 million in the first half, so it is still growing modestly. The real test is whether Opzelura and the newer drugs can grow fast enough before the 2028 patent expiries. Q2's underlying numbers are encouraging: those products grew 24% and 69%, and the company kept its R&D growth to 4.5%. The next few quarters depend on the approval decisions above (tafasitamab first-line and povorcitinib, both targeting Q1 2027) and on the ten data readouts promised for H2 2026.
Source: Incyte Form 10-Q for the quarter ended June 30, 2026 (filed July 28, 2026); guidance from the Q2 2026 earnings release, 8-K Exhibit 99.1 (July 28, 2026). Figures exclusive of the one-time items are our own calculations from line items in the filing.